On October 16, 2023 VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, reported that it is presenting three scientific abstracts at ESMO (Free ESMO Whitepaper) 2023, the annual congress of the European Society for Medical Oncology (Press release, VolitionRX, OCT 16, 2023, View Source [SID1234636026]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Jake Micallef, Chief Scientific Officer at Volition, said: "We are delighted to be attending ESMO (Free ESMO Whitepaper) 2023 and have the opportunity to share exciting new data in lung cancer and glioblastoma, and introduce what we believe to be an entirely new method for the detection of cancer."
On Saturday 21st October, Dr. Dorian Pamart, Head of Technology and Service Unit at Volition, will present a poster (205P) titled ‘A novel immunoprecipitation/PCR method for detection of plasma cfDNA fragments selectively occupied by CTCF in cancer’.
On Sunday 22nd October, Dr. Pei-Hsing Chen from National Taiwan University Hospital will present a mini oral session (133MO) titled ‘Differentiation of malignant and benign lung nodules using epigenetically modified nucleosomes in plasma’ in the Santander Auditorium, hall 9 at 9.30 am. The study was undertaken by Volition and the National Taiwan University Hospital and is part of a longer-term research collaboration.
In addition, Jonathan Decarpentrie, from the Research Institute for Life Sciences, University of Namur will present a poster (524P) titled ‘Cell line study of nucleosome-based biomarkers in the diagnosis and detection of relapses in glioblastoma’. Volition and biotechnology company, Qualiblood have worked in collaboration with University of Namur on this latest study.
Abstract summary:
Date
Presentation Title
Presentation
Number
Presentation
type
Sat 21st
October
A novel immunoprecipitation/PCR method for
detection of plasma cfDNA fragments selectively
occupied by CTCF in cancer’.
205P
Poster
Sun 22nd
October
Differentiation of malignant and benign lung nodules
using epigenetically modified nucleosomes in
plasma.
133MO
Mini oral
session
Sun 22nd
October
Cell line study of nucleosome-based biomarkers in
the diagnosis and detection of relapses in
glioblastoma
524P
Poster
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases in both humans and animals. For more information about Volition’s technology go to: www.volition.com